Feldman and Pike’s Vitamin D (5^th Ed.) Volume Two: Disease and Therapeutics

51. Defining thresholds for vitamin D I: scientific rationale for serum 25-hydroxyvitamin D cutoffs of 25 and 50 nmol/L;
52. Defining thresholds for vitamin D II;
53. Methods of evaluating population studies of vitamin D: strengths and weaknesses;
54. Worldwide vitamin D status;
55. Vitamin D in fooddCompounds, stability, sources;
56. Determinants of vitamin D levels from sun exposure: a global perspective;
57. Vitamin D supplement use as a public health strategy to augment diet and sustain population adequacy;
58. Vitamin D and food fortification;
59. Bariatric surgery, vitamin D, and bone loss;
60. Genetic determinants of 25-hydroxyvitamin D concentrations;
61. Effect of vitamin D on health and disease: evidence from Mendelian randomization;
62. Growth plate histology, bone histomorphometry, and radiologic features of nutritional rickets and osteomalacia;
63. Vitamin D deficiency and nutritional rickets in infants and children;
64. Clinical disorders of phosphate homeostasis;
65. The hypocalcemic disorders;
66. Vitamin D hydroxylationedeficient rickets, type 1A;
67. The role of genetic variation in CYP2R1, the principal vitamin D 25- hydroxylase, and CYP3A4 in vitamin D homeostasis;
68. Hereditary 1,25-dihydroxyvitamin D resistant rickets (VDDR-2A);
69. Infantile hypercalcemia and CYP24A1 mutations;
70. Vitamin D and osteoporosis;
71. Adult vitamin D deficiencydfracture and fall prevention: findings from randomized controlled trials;
72. Randomized clinical trials of vitamin D and bone health;
73. Calcifediol as a therapeutic;
74. Vitamin D and organ transplantation;
75. Vitamin D, obesity, the metabolic syndrome and its sequelae;
76. The role of vitamin D in type 2 diabetes;
77. Liver metabolism and disease;
78. Vitamin D, hypertension, and cardiovascular disease;
79. Vitamin D and renal disease;
80. Vitamin D and kidney stones;
81. Hypercalcemia due to vitamin D toxicity;
82. Vitamin D and Paget’s disease;
83. Vitamin D metabolism and disorders in companion animals;
84. Overview of vitamin D actions in cancer;
85. Vitamin D status and cancer incidence, mortality, and prognosis;
86. Antiproliferative and immunoregulatory actions of vitamin D derivatives on hematological malignancies: control of differentiation, proliferation, and cell death;
87. Vitamin D, inflammation, and cancer;
88. Vitamin D actions in mammary gland and breast cancer;
89. Vitamin D and colorectal cancer;
90. Vitamin D in the management of lung cancer: influence of tumor stage, tumor genotype, and treatment modality;
91. Vitamin D and prostate cancer;
92. Vitamin D and pancreatic cancer;
93. Sunlight, skin cancer and vitamin D;
94 . Vitamin D and antibacterial immunity;
95. Vitamin D and antiviral immunity;
96. Vitamin D and adaptive immunity in health and disease;
97. Vitamin D, microbiota, and inflammatory bowel disease;
98. Vitamin D and tuberculosis;
99. The role of vitamin D in COVID-19;
100 . Vitamin D and type 1 diabetes;
101. Vitamin D mechanisms of protection in multiple sclerosis;
102. Vitamin D and the epidemiology of multiple sclerosis;
103. Vitamin D and rheumatoid arthritis;
104. Psoriasis and other skin disorders;
105. Vitamin D, acute respiratory infection, and Asthma/COPD;
106. Vitamin D and acute illness;
Index for Volume 2

Prof. Hewison’s work focuses on different facets of vitamin D physiology, including classical skeletal effects and non-classical extra-skeletal effects. He has a particular interest in the interaction between vitamin D and the immune system, where antigen-presenting cells such as dendritic cells and macrophages synthesize active vitamin D (calcitriol) and also express the nuclear receptor for calcitriol (VDR). Vitamin D can therefore act as an endogenous regulator of both innate and adaptive immunity by enhancing antibacterial activity, and modulating antigen presentation and T lymphocyte function. Crucially these responses are highly dependent on the bioavailability of vitamin D, and Prof. Hewison has hypothesized that immune function is influenced by vitamin D status in humans. His group is using a variety of models to test this hypothesis including basic molecular and cell analyses, and vitamin D supplementation trials in human cohorts. A key objective of his work is to increase awareness of vitamin D-deficiency in the UK population.
Roger Bouillon, MD, PhD, FRCP, biography Roger Bouillon is professor (emeritus since 2010) in endocrinology (internal medicine) at the University and University Hospital of the Catholic University of Leuven (K.U.Leuven) in Belgium. He is a member of the Royal Academy of Medicine (Belgium) and a Fellow of the Royal College of Physicians (London). He was a founding member and later President of the European Board of Endocrinology (UEMS 1988-2002). He was a member of several European Science Foundation Committees (Board member of the European Medical Research Council) and of the European Space Agency Life Science working group till 2012. He is past-president of the International Bone and Mineral Society (2011-13 ) and is co-organizer of the vitamin D workshop. He was vice president for research of the University of Leuven from 1995-2005. He is coauthor of more than 500 peer reviewed articles that generated about 26,000 ISI citations